These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21417735)

  • 21. Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matrices.
    Myler H; Rangan VS; Kozhich A; Hoffpauir B; Dail D; Cummings J; Saewert M; Manney A; Liu A; Rao C; Wang J; Pillutla R; DeSilva B
    Bioanalysis; 2016 Mar; 8(6):519-31. PubMed ID: 26915587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.
    Kumar S; King LE; Clark TH; Gorovits B
    Bioanalysis; 2015; 7(13):1605-17. PubMed ID: 26226310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
    Lin K; Tibbitts J; Shen BQ
    Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
    Harper J; Mao S; Strout P; Kamal A
    Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Mass Spectrometric Tools for the Bioanalyses of Therapeutic Monoclonal Antibodies and Antibody-Drug Conjugates.
    Todoroki K; Yamada T; Mizuno H; Toyo'oka T
    Anal Sci; 2018; 34(4):397-406. PubMed ID: 29643301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.
    Xu K; Liu L; Dere R; Mai E; Erickson R; Hendricks A; Lin K; Junutula JR; Kaur S
    Bioanalysis; 2013 May; 5(9):1057-71. PubMed ID: 23641696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo testing of drug-linker stability.
    Abecassis PY; Amara C
    Methods Mol Biol; 2013; 1045():101-16. PubMed ID: 23913143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates.
    Farias SE; Strop P; Delaria K; Galindo Casas M; Dorywalska M; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2014 Feb; 25(2):240-50. PubMed ID: 24359082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.
    Lu D; Sahasranaman S; Zhang Y; Girish S
    Bioanalysis; 2013 May; 5(9):1115-30. PubMed ID: 23641700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future.
    Beck A; D'Atri V; Ehkirch A; Fekete S; Hernandez-Alba O; Gahoual R; Leize-Wagner E; François Y; Guillarme D; Cianférani S
    Expert Rev Proteomics; 2019 Apr; 16(4):337-362. PubMed ID: 30706723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the construction of antibody-drug conjugates.
    Chudasama V; Maruani A; Caddick S
    Nat Chem; 2016 Feb; 8(2):114-9. PubMed ID: 26791893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical de-conjugation for investigating the stability of small molecule drugs in antibody-drug conjugates.
    Chen T; Su D; Gruenhagen J; Gu C; Li Y; Yehl P; Chetwyn NP; Medley CD
    J Pharm Biomed Anal; 2016 Jan; 117():304-10. PubMed ID: 26406314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry.
    Valliere-Douglass JF; Hengel SM; Pan LY
    Mol Pharm; 2015 Jun; 12(6):1774-83. PubMed ID: 25474122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioanalytical Assays for Pharmacokinetic and Biodistribution Study of Antibody-Drug Conjugates.
    Yin L; Xu A; Zhao Y; Gu J
    Drug Metab Dispos; 2023 Oct; 51(10):1324-1331. PubMed ID: 37290939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.
    Kraynov E; Kamath AV; Walles M; Tarcsa E; Deslandes A; Iyer RA; Datta-Mannan A; Sriraman P; Bairlein M; Yang JJ; Barfield M; Xiao G; Escandon E; Wang W; Rock DA; Chemuturi NV; Moore DJ
    Drug Metab Dispos; 2016 May; 44(5):617-23. PubMed ID: 26669328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates.
    Matsuda Y; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2021; 69(10):976-983. PubMed ID: 34602579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study.
    Myler H; Rangan VS; Wang J; Kozhich A; Cummings JA; Neely R; Dail D; Liu A; Wang B; Vezina HE; Freebern W; Sung MC; Passmore D; Deshpande S; Kempe T; Gu H; Saewert M; Manney A; Lute J; Zambito F; Wong RL; Piccoli SP; Aubry AF; Pillutla R; Arnold M; DeSilva B
    Bioanalysis; 2015; 7(13):1569-82. PubMed ID: 26226308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.